|Day Low/High||21.75 / 23.50|
|52 Wk Low/High||8.30 / 53.46|
Quite a few stocks are fading right now -- not due to poor fundamentals, but due to lack of buying interest.
The action so far looks to be driven more by fear of being left out than euphoric chasing.
So far today, aggressive stock picking is looking like a possibility.
The biggest problem for stock pickers is that there still aren't any good themes.
A few of these names continue to look good in 2021.
It has not been a smooth transition between 'reopening' and 'stay-at-home' stocks.
The positive news is that small-caps continue to do well and there's some good trading in smaller names.
Market players don't want to be aggressive or have large exposure until we see greater election clarity.
Here's what's on my radar as market players continue to be optimistic about the prospects of individual stocks into earnings.
Smaller stocks that were big winners are coming back down right now, and here are some on my screen.
The primary focus is on trying to put more cash to work.
This is a very healthy market and some consolidations and pullbacks would be advantageous for trading.
This is the same sort of rotation that we saw in early September.
There are a couple of things that are helping to contain the selling.
There a several names that I expect to see strong earnings results from.
This isn't a market with a lot of very extended stocks so the chances of catching some names at support are good.
I'm not going to be distracted by all the whining about the 'big picture'.
Shares of the biotech firm Personalis could soar higher in the months ahead.
Don't be in a rush. The key to accumulating stocks in this environment is to move incrementally.
One is Abbott Labs' announcement of a quick and cheap Covid test.
Here are several names I'm looking to build on further weakness.
The hardest thing to do is to stick with the momentum and not give in to the temptation to sell prematurely.
While breadth is very good Wednesday, it isn't flowing into the speculative names.
There's nothing in the price action to indicate that a change in market character is developing.
Biotechnology is always high risk but the right plays move unlike anything else.